Brian R. Bettencourt

1 ta ish

Alnylam Pharmaceuticals (United States)

1. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

   Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya +17

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.051496